JP2012533560A - 細胞における取り込みが制御可能なペプチド - Google Patents

細胞における取り込みが制御可能なペプチド Download PDF

Info

Publication number
JP2012533560A
JP2012533560A JP2012520795A JP2012520795A JP2012533560A JP 2012533560 A JP2012533560 A JP 2012533560A JP 2012520795 A JP2012520795 A JP 2012520795A JP 2012520795 A JP2012520795 A JP 2012520795A JP 2012533560 A JP2012533560 A JP 2012533560A
Authority
JP
Japan
Prior art keywords
molecule
peptide
amino acids
sequence
selective transport
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012520795A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012533560A5 (enExample
Inventor
ロジャー チェン
トッド アギレラ
エミリア オルソン
タオ ジャン
クエン グエン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
University of California, Los Angeles
Original Assignee
University of California, San Diego
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California, San Diego filed Critical University of California, San Diego
Publication of JP2012533560A publication Critical patent/JP2012533560A/ja
Publication of JP2012533560A5 publication Critical patent/JP2012533560A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/595—Polyamides, e.g. nylon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056—Peptides, proteins, polyamino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2012520795A 2009-07-15 2010-07-15 細胞における取り込みが制御可能なペプチド Pending JP2012533560A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22587209P 2009-07-15 2009-07-15
US61/225,872 2009-07-15
PCT/US2010/042184 WO2011008992A2 (en) 2009-07-15 2010-07-15 Peptides whose uptake in cells is controllable

Publications (2)

Publication Number Publication Date
JP2012533560A true JP2012533560A (ja) 2012-12-27
JP2012533560A5 JP2012533560A5 (enExample) 2013-08-29

Family

ID=43450218

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012520795A Pending JP2012533560A (ja) 2009-07-15 2010-07-15 細胞における取り込みが制御可能なペプチド

Country Status (7)

Country Link
US (4) US9682151B2 (enExample)
EP (2) EP2453926A4 (enExample)
JP (1) JP2012533560A (enExample)
CN (1) CN102858794A (enExample)
AU (1) AU2010273321A1 (enExample)
CA (1) CA2770980A1 (enExample)
WO (2) WO2011008992A2 (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016516000A (ja) * 2013-01-30 2016-06-02 アベラス バイオサイエンシーズ，インク． 選択的な送達分子及びその使用方法
JP2016528908A (ja) * 2013-08-30 2016-09-23 ノヴォ ノルディスク アー／エス 小分子を用いるヒト多能性幹細胞からの内分泌始原細胞の作製
JP2017530131A (ja) * 2014-09-26 2017-10-12 ザ サウス アフリカン ニュークリア エナジー コーポレーション リミテッドＴｈｅ Ｓｏｕｔｈ Ａｆｒｉｃａｎ Ｎｕｃｌｅａｒ Ｅｎｅｒｇｙ Ｃｏｒｐｏｒａｔｉｏｎ Ｌｉｍｉｔｅｄ 腫瘍細胞を標的にするための代謝産物およびｅｐｒ剤の放射性医薬品コンジュゲート
KR20210098449A (ko) * 2018-11-29 2021-08-10 스타파마 피티와이 리미티드 요법 및 영상화를 위한 덴드리머

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9695251B2 (en) 2003-10-31 2017-07-04 The Regents Of The University Of California Activatable cell penetrating peptides with quenched fluorophores
US7985401B2 (en) * 2003-10-31 2011-07-26 The Regents Of The University Of California Peptides whose uptake by cells is controllable
US8153435B1 (en) 2005-03-30 2012-04-10 Tracer Detection Technology Corp. Methods and articles for identifying objects using encapsulated perfluorocarbon tracers
EP4032538A3 (en) 2009-03-02 2022-10-26 Massachusetts Institute of Technology Methods and products for in vivo enzyme profiling
US9682151B2 (en) 2009-07-15 2017-06-20 The Regents Of The University Of California Peptides whose uptake in cells is controllable
ES2881535T3 (es) 2011-03-15 2021-11-29 Massachusetts Inst Technology Detección multiplexada con indicadores codificados con isótopos
CN103874512B (zh) * 2011-07-29 2016-11-16 艾维拉斯生物科学公司 选择性递送分子及使用方法
US8871189B2 (en) 2011-11-30 2014-10-28 Mallinckrodt Llc MMP-targeted therapeutic and/or diagnostic nanocarriers
US9355654B1 (en) 2012-12-21 2016-05-31 Western Digital Technologies, Inc. Spin torque oscillator for microwave assisted magnetic recording with increased damping
WO2014120837A2 (en) 2013-01-29 2014-08-07 The Regents Of The University Of California Pretargeted activatable cell penetrating peptide with intracellulary releaseable prodrug
MX370538B (es) 2013-03-27 2019-12-17 Hoffmann La Roche Marcadores genéticos para la predicción de respuesta a la terápia.
EP2988786A4 (en) * 2013-04-22 2016-12-21 Avelas Biosciences Inc COMPOSITIONS FOR SELECTIVE DRUG ADMINISTRATION AND METHOD OF USE
WO2014183119A1 (en) * 2013-05-10 2014-11-13 H. Lee Moffitt Cancer Center And Research Institute, Inc. Molecular imaging probes for lung cancer inoperative guidance
JP6847660B2 (ja) 2013-06-07 2021-03-24 マサチューセッツ インスティテュート オブ テクノロジー リガンドをコードする合成バイオマーカーのアフィニティベースの検出
WO2015038493A1 (en) * 2013-09-10 2015-03-19 The Research Foundation For The State University Of New York Synthesis of novel asymmetric bow-tie pamam dendrimer-based conjugates for tumor-targeting drug delivery
WO2016016157A1 (en) 2014-07-30 2016-02-04 F. Hoffmann-La Roche Ag Genetic markers for predicting responsiveness to therapy with hdl-raising or hdl mimicking agent
CN104792979B (zh) * 2014-09-05 2017-02-01 昆明医科大学第一附属医院 一种检测人基质金属蛋白酶‑12活性的荧光多肽底物
US10385380B2 (en) 2014-10-02 2019-08-20 The Regents Of The University Of California Personalized protease assay to measure protease activity in neoplasms
US10596259B2 (en) 2015-05-20 2020-03-24 The Regents Of The University Of California Tumor radiosensitization with monomethyl auristatin E (MMAE) and derivatives thereof
EP3440013A4 (en) 2016-04-08 2021-03-17 Massachusetts Institute of Technology METHOD FOR SPECIFIC PROFILING OF PROTEASE ACTIVITY ON LYMPH NODES
WO2017193070A1 (en) 2016-05-05 2017-11-09 Massachusetts Institute Of Technology Methods and uses for remotely triggered protease activity measurements
CA3087881A1 (en) 2017-01-17 2018-07-26 Michael David FORREST Therapeutic inhibitors of the reverse mode of atp synthase
AU2018248327B2 (en) 2017-04-07 2024-10-10 Massachusetts Institute Of Technology Methods to spatially profile protease activity in tissue and sections
CA3099077A1 (en) 2017-07-13 2019-01-17 Michael David FORREST Therapeutic modulators of the reverse mode of atp synthase
WO2019173332A1 (en) 2018-03-05 2019-09-12 Massachusetts Institute Of Technology Inhalable nanosensors with volatile reporters and uses thereof
WO2019204363A2 (en) * 2018-04-16 2019-10-24 Avelas Biosciences, Inc. Selective delivery of therapeutic and imaging agents
EP3856921B1 (en) 2018-09-25 2026-04-29 Massachusetts Institute Of Technology Lung protease nanosensors and uses thereof
EP3628309A1 (en) * 2018-09-28 2020-04-01 Universität Heidelberg Method of making oral dosage forms
EP3911753A1 (en) 2019-01-17 2021-11-24 Massachusetts Institute of Technology Sensors for detecting and imaging of cancer metastasis
IT201900002321A1 (it) * 2019-02-18 2020-08-18 Univ Degli Studi Padova Peptidi con attivita' antitumorale
AU2021284918A1 (en) * 2020-06-03 2023-01-05 Starpharma Pty Ltd Therapeutic conjugates
EP4211468A4 (en) 2020-09-11 2024-10-09 Glympse Bio, Inc. DETECTION OF EX VIVO PROTEASE ACTIVITY FOR DETECTION/DIAGNOSTIC, STAGING, MONITORING AND TREATMENT OF DISEASES
US20250325469A1 (en) 2021-01-24 2025-10-23 Michael David FORREST Inhibitors of atp synthase - cosmetic and therapeutic uses
CN115385988B (zh) * 2022-05-25 2023-04-11 广州医科大学 一种mmp酶响应型肿瘤靶向多肽载体及其应用
CN116063389B (zh) * 2022-08-23 2023-07-07 广州医科大学 递送核酸药物的多肽载体、治疗肿瘤的核酸药物及其制备方法
WO2024049306A1 (en) * 2022-08-31 2024-03-07 Lopez Gonzalez Ricardo Chemical conjugates, compositions, and methods of preparation and use thereof
CN120417945A (zh) * 2022-11-14 2025-08-01 阿克提斯肿瘤学公司 肾脏中小蛋白滞留的减少
KR20260085122A (ko) 2023-09-29 2026-06-08 악티스 온콜로지, 인크. 미니단백질, 접합체 및 이의 용도
CN118955414B (zh) * 2024-10-17 2025-03-18 南昌大学 两亲性Eu配合物及其制备方法与在检测四环素中的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070041904A1 (en) * 2003-10-31 2007-02-22 Tao Jiang Peptides whose uptake by cells is controllable
JP2007511209A (ja) * 2003-10-31 2007-05-10 ザ・レジェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア 細胞による取り込みが制御可能なペプチド

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4507389A (en) 1982-12-16 1985-03-26 Monsanto Company Determination of collagenase by reacting with peptide substrates
US4466919A (en) 1982-12-16 1984-08-21 Monsanto Company Peptide substrates for mammalian collagenase
GB8927722D0 (en) 1989-12-07 1990-02-07 British Bio Technology Proteins and nucleic acids
US5670617A (en) 1989-12-21 1997-09-23 Biogen Inc Nucleic acid conjugates of tat-derived transport polypeptides
DE69628731T3 (de) 1995-11-01 2012-09-20 Bracco Suisse S.A. Gezielte magnetisch markierte molekularmarkersysteme als nmr-bilderzeugungsmittel
US6214966B1 (en) 1996-09-26 2001-04-10 Shearwater Corporation Soluble, degradable poly(ethylene glycol) derivatives for controllable release of bound molecules into solution
GB9708265D0 (en) * 1997-04-24 1997-06-18 Nycomed Imaging As Contrast agents
ES2210761T3 (es) 1997-05-21 2004-07-01 The Board Of Trustees Of The Leland Stanford Junior University Composicion y procedimiento para mejorar el transporte a traves de las membranas biologicas.
US6592847B1 (en) 1998-05-14 2003-07-15 The General Hospital Corporation Intramolecularly-quenched near infrared flourescent probes
US6083486A (en) 1998-05-14 2000-07-04 The General Hospital Corporation Intramolecularly-quenched near infrared fluorescent probes
JP2002518521A (ja) 1998-06-20 2002-06-25 ワシントン・ユニバーシティ 医用画像解析、診断および治療のための膜透過性ペプチド錯体
US6436703B1 (en) 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
US20020009786A1 (en) 2000-04-18 2002-01-24 Tang Y. Tom Novel nucleic acids and polypeptides
US6737247B2 (en) * 2000-10-19 2004-05-18 The General Hospital Corporation Imaging of enzymatic activity
US7179784B2 (en) 2001-07-10 2007-02-20 Massachusetts Institute Of Technology Surfactant peptide nanostructures, and uses thereof
WO2004042034A2 (en) 2002-11-04 2004-05-21 Fred Hutchinson Cancer Research Center Method for the linear amplification of complementary dna
WO2005019247A2 (en) 2003-08-15 2005-03-03 Board Of Regents, The University Of Texas System Cyclic peptide and imaging compound compositions and uses for targeted imaging and therapy
US9695251B2 (en) 2003-10-31 2017-07-04 The Regents Of The University Of California Activatable cell penetrating peptides with quenched fluorophores
ES2605443T3 (es) 2003-11-06 2017-03-14 Seattle Genetics, Inc. Conjugados de auristatina con anticuerpos anti-HER2 o anti-CD22 y su uso en terapia
CA2583389A1 (en) * 2004-10-07 2006-04-20 Emory University Multifunctional nanoparticles conjugates and their use
TW201004647A (en) 2008-05-20 2010-02-01 Sigma Tau Ind Farmaceuti Novel dual targeting antitumoural conjugates
KR101095841B1 (ko) 2009-02-19 2011-12-21 주식회사 나이벡 표적 선택적 세포／조직 투과기능 활성을 가지는 펩타이드 및 그 용도
US9682151B2 (en) * 2009-07-15 2017-06-20 The Regents Of The University Of California Peptides whose uptake in cells is controllable
JP5646923B2 (ja) 2010-09-03 2014-12-24 矢崎総業株式会社 車両用表示装置及び車両用表示システム
CN103874512B (zh) 2011-07-29 2016-11-16 艾维拉斯生物科学公司 选择性递送分子及使用方法
WO2014120837A2 (en) 2013-01-29 2014-08-07 The Regents Of The University Of California Pretargeted activatable cell penetrating peptide with intracellulary releaseable prodrug

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070041904A1 (en) * 2003-10-31 2007-02-22 Tao Jiang Peptides whose uptake by cells is controllable
JP2007511209A (ja) * 2003-10-31 2007-05-10 ザ・レジェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア 細胞による取り込みが制御可能なペプチド

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JPN6015022431; ＰＮＡＳ． Ｖｏｌ．１０７，　Ｎｏ．９, 20100216, ｐ．４３１１-４３１６ *
JPN6015048997; ＯＬＳＯＮ，　Ｅ．Ｓ．: 'Ａｃｔｉｖａｔａｂｌｅ　ｃｅｌｌ　ｐｅｎｅｔｒａｔｉｎｇ　ｐｅｐｔｉｄｅｓ　ｆｏｒ　ｉｍａｇｉｎｇ　ｐｒｏｔｅａｓｅ　ａｃｔｉｖｉｔｙ　ｉｎ　ｖｉｖｏ' ｅＳｃｈｏｌａｒｓｈｉｐ　［ｏｎｌｉｎｅ］ , 2008 *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016516000A (ja) * 2013-01-30 2016-06-02 アベラス バイオサイエンシーズ，インク． 選択的な送達分子及びその使用方法
JP2016528908A (ja) * 2013-08-30 2016-09-23 ノヴォ ノルディスク アー／エス 小分子を用いるヒト多能性幹細胞からの内分泌始原細胞の作製
JP2017530131A (ja) * 2014-09-26 2017-10-12 ザ サウス アフリカン ニュークリア エナジー コーポレーション リミテッドＴｈｅ Ｓｏｕｔｈ Ａｆｒｉｃａｎ Ｎｕｃｌｅａｒ Ｅｎｅｒｇｙ Ｃｏｒｐｏｒａｔｉｏｎ Ｌｉｍｉｔｅｄ 腫瘍細胞を標的にするための代謝産物およびｅｐｒ剤の放射性医薬品コンジュゲート
KR20210098449A (ko) * 2018-11-29 2021-08-10 스타파마 피티와이 리미티드 요법 및 영상화를 위한 덴드리머
JP2022513630A (ja) * 2018-11-29 2022-02-09 スターファーマ ピーティーワイ エルティーディー 治療および画像化のためのデンドリマー
JP7541978B2 (ja) 2018-11-29 2024-08-29 スターファーマ ピーティーワイ エルティーディー 治療および画像化のためのデンドリマー
KR102940818B1 (ko) * 2018-11-29 2026-03-18 스타파마 피티와이 리미티드 요법 및 영상화를 위한 덴드리머

Also Published As

Publication number Publication date
US11246940B2 (en) 2022-02-15
EP2453926A4 (en) 2015-08-12
AU2010273321A1 (en) 2012-03-08
US9808532B2 (en) 2017-11-07
WO2011008996A3 (en) 2011-05-26
US20120134931A1 (en) 2012-05-31
EP2454271A4 (en) 2015-08-12
US20120134922A1 (en) 2012-05-31
EP2453926A2 (en) 2012-05-23
US20200046843A1 (en) 2020-02-13
WO2011008992A3 (en) 2011-06-30
CN102858794A (zh) 2013-01-02
US9682151B2 (en) 2017-06-20
US20170305968A1 (en) 2017-10-26
CA2770980A1 (en) 2011-01-20
EP2454271A2 (en) 2012-05-23
WO2011008992A2 (en) 2011-01-20
WO2011008996A2 (en) 2011-01-20

Similar Documents

Publication Publication Date Title
US11246940B2 (en) Peptides whose uptake in cells is controllable
US10029017B2 (en) Pretargeted activatable cell penetrating peptide with intracellularly releasable prodrug
Qi et al. Self‐assembled peptide‐based nanomaterials for biomedical imaging and therapy
Wang et al. MMP-2-controlled transforming micelles for heterogeneic targeting and programmable cancer therapy
Lock et al. One-component supramolecular filament hydrogels as theranostic label-free magnetic resonance imaging agents
Guo et al. Functional alginate nanoparticles for efficient intracellular release of doxorubicin and hepatoma carcinoma cell targeting therapy
US10259845B2 (en) Peptides whose uptake by cells is controllable
Jenkins et al. Mini-review: fluorescence imaging in cancer cells using dye-doped nanoparticles
Shim et al. Comparative study of cathepsin B-cleavable linkers for the optimal design of cathepsin B-specific doxorubicin prodrug nanoparticles for targeted cancer therapy
US20100267928A1 (en) Activatable diagnostic and therapeutic compound
US10058622B2 (en) PH-sensitive peptides and their nanoparticles for drug delivery
Li et al. Nanoparticle binding to urokinase receptor on cancer cell surface triggers nanoparticle disintegration and cargo release
Li et al. A self-assembled affibody-PROTAC conjugate nanomedicine for targeted cancer therapy
Jiang et al. A supramolecular nanocarrier for efficient cancer imaging and therapy by targeting at matriptase
An et al. Peptide-based nanostructures for cancer diagnosis and therapy
Cordova et al. Aminopeptidase P mediated targeting for breast tissue specific conjugate delivery
Wang et al. A Modular Platform for Enhanced Drug Delivery to Glioblastoma Using Targeted Multidomain Protein Assemblies
US20170224833A1 (en) Self-assembling molecules that accumulate in acidic tumor microenvironments
KR20200135224A (ko) 마이셀 구조의 나노 전달체 및 이의 용도
Dong et al. Systematic evaluation and hepatic targeting of a dual-fluorescence icaritin microemulsion: elucidating the protein corona-mediated delivery mechanism
WO2024259158A2 (en) Lipid nanoparticles for peptide delivery and methods of making and using the same
WO2025177270A1 (en) Blood-brain barrier permeable shuttle and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121207

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130710

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130710

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20141029

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150128

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20150331

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150604

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150901

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20151203

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20160511